Cagrilintide 10mg Kit of 10

Cagrilintide is a long-acting synthetic analog of amylin, a hormone that is naturally released by the pancreas alongside insulin after meals. It is being investigated for its effects on appetite regulation and weight management and has also been studied in combination with semaglutide. Cagrilintide is not currently approved by the U.S. FDA as a standalone medication.

What is Cagrilintide?

• Cagrilintide is a long-acting amylin receptor agonist.
• It is designed to mimic the actions of the natural hormone amylin, while remaining active in the body much longer.
• It is typically administered by subcutaneous injection in clinical research.

What Does Amylin Do?

Amylin is a hormone released by pancreatic beta cells along with insulin. It helps regulate blood sugar and food intake by:

• Slowing gastric (stomach) emptying.
• Increasing feelings of fullness (satiety).
• Reducing food intake.
• Suppressing glucagon secretion after meals.

These physiological effects make amylin an area of interest in obesity and metabolic disease research.

Areas of Clinical Research

Researchers have studied cagrilintide for:

Weight Management

• Cagrilintide has been evaluated in clinical trials for chronic weight management in adults with overweight or obesity.
• Studies have found that participants receiving cagrilintide generally lost more weight than those receiving placebo, alongside diet and exercise.

Appetite Regulation

Research suggests cagrilintide may:

• Reduce hunger.
• Increase feelings of fullness.
• Help reduce overall calorie intake.

Combination with Semaglutide

One major area of research has examined combining cagrilintide with semaglutide, a GLP-1 receptor agonist.

The rationale is that:

• Semaglutide and cagrilintide act through different biological pathways.
• Combining them may produce greater weight loss than either alone.

This combination has been studied under the investigational name CagriSema.

Mechanism of Action

Cagrilintide primarily works by activating amylin receptors in the brain and gastrointestinal tract.

Its effects may include:

• Delayed gastric emptying.
• Increased satiety.
• Reduced appetite.
• Lower food intake.
• Reduced post-meal glucagon secretion.

These mechanisms contribute to its investigation as a treatment for obesity and metabolic disorders.

Clinical Evidence

Unlike many research peptides, cagrilintide has been evaluated in multiple Phase 2 and Phase 3 clinical trials.

Clinical trials have reported:

• Significant average weight loss in participants with obesity.
• Greater weight loss when combined with semaglutide compared with semaglutide alone in some studies.

Although the evidence base is stronger than for many experimental peptides, regulatory review is still ongoing for investigational combinations.

Research Use Only: This product is intended solely for legitimate laboratory and scientific research. It is not intended for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease. This product has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). Handle only by qualified research professionals in accordance with applicable laws and regulations.